Skip to content
Head to head

Summit Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: SMMT · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

SMMT -41.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
SMMTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price9.95515.02
Change today-5.87%-1.08%
1-year return-39.5%+22.0%
Market cap$7.96B$130.58B
52-week range9.89 – 29.23412.27 – 568.67
Valuation
P/E (TTM)-9.3933.14
P/E percentile, own 5-yr range44th99th
P/B14.096.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.4415.32
Net profit (TTM)$-1.15B$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin100.0%85.5%
Operating margin-27618.6%33.1%
Net margin-271685.0%30.7%
Free cash flow (TTM)$-526.88M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership21.2%96.8%
Insider activity (12mo)49 buy / 0 sell28 buy / 22 sell
Short interest (% of float)5.3%1.9%
Analyst consensus62% buy / 31% hold / 8% sell (13)95% buy / 5% hold (21)
Analyst price target$28 (+177%)$624 (+21%)
StockVane view
StockVane Quant RatingE (10)C (68)
Company
Employees2656,400
Founded20031989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.